GH Research (NASDAQ:GHRS) Receives “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 228.41% from the company’s previous close.

Separately, Canaccord Genuity Group raised their price objective on shares of GH Research from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, May 6th.

GH Research Stock Performance

NASDAQ:GHRS opened at $12.18 on Wednesday. The company has a market capitalization of $633.73 million, a PE ratio of -19.64 and a beta of 0.86. The company has a 50 day simple moving average of $12.26 and a two-hundred day simple moving average of $10.56. GH Research has a fifty-two week low of $5.05 and a fifty-two week high of $14.99.

GH Research (NASDAQ:GHRS) last released its earnings results on Friday, May 3rd. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Research analysts predict that GH Research will post -0.84 EPS for the current year.

Institutional Trading of GH Research

Hedge funds have recently bought and sold shares of the business. AdvisorShares Investments LLC grew its position in GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in GH Research by 14.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after purchasing an additional 13,579 shares during the period. Lynx1 Capital Management LP grew its position in GH Research by 80.1% in the 1st quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock valued at $35,291,000 after purchasing an additional 1,471,946 shares during the period. RA Capital Management L.P. grew its position in GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after purchasing an additional 664,381 shares during the period. Finally, BVF Inc. IL grew its position in GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after purchasing an additional 1,125,000 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).